Dawnzera is the first and only RNA-targeted prophylactic therapy to be approved for hereditary angioedema in adults and ...

A new study suggests an enzyme unique to Homo sapiens may have made us more competitive water seekers than our closest ...

Dawnzera is the first and so far only RNA-targeting therapy approved as a prophylactic treatment for hereditary angioedema ...

Over the last few years, scientists and entrepreneurs have flocked to developing medicines that target RNA, the genetic ...

Merck KGaA agreed to a deal with RNA biotech Skyhawk Therapeutics that could top out at $2 billion. Roche’s Genentech terminated a cell therapy partnership with Adaptive Biotechnologies, ending what ...

The US Food and Drug Administration (FDA) has approved Dawnzera (donidalorsen) for prophylaxis to prevent attacks of ...

Yale researchers have developed a new and safe family of RNA-editing tools that utilize an RNA-targeting activity that they ...

The US Food and Drug Administration (FDA) has approved Ionis Pharmaceuticals’ RNA-targeted prophylactic treatment, Dawnzera ...

In the wake of funding cuts to mRNA vaccine research, we revisit a February story about a promising vaccine for pancreatic ...

Researchers at MIT have developed a new AI method to design nanoparticles that can deliver RNA vaccines and other RNA-based treatments more effectiv ...